Citigroup Inc Nautilus Biotechnology, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Nautilus Biotechnology, Inc. stock. As of the latest transaction made, Citigroup Inc holds 38,982 shares of NAUT stock, worth $69,387. This represents 0.0% of its overall portfolio holdings.

Number of Shares

38,982

Previous 14,458 169.62%

Holding current value

$69,387

Previous $33,000 236.36%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$2.24 - $3.08 $54,933 - $75,533	24,524 Added 169.62%	38,982 $111,000
Q2 2024 Aug 12, 2024	BUY	$2.22 - $3.0 $8,131 - $10,989	3,663 Added 33.93%	14,458 $33,000
Q1 2024 May 10, 2024	BUY	$2.41 - $3.18 $920 - $1,214	382 Added 3.67%	10,795 $31,000
Q4 2023 Feb 09, 2024	BUY	$2.34 - $3.39 $18,221 - $26,397	7,787 Added 296.53%	10,413 $31,000
Q3 2023 Nov 09, 2023	SELL	$2.87 - $3.94 $44,008 - $60,415	-15,334 Reduced 85.38%	2,626 $8,000
Q2 2023 Aug 10, 2023	BUY	$2.21 - $4.52 $34,765 - $71,104	15,731 Added 705.74%	17,960 $69,000
Q1 2023 May 11, 2023	SELL	$1.67 - $2.77 $764 - $1,268	-458 Reduced 17.05%	2,229 $6,000
Q4 2022 Feb 09, 2023	SELL	$1.55 - $2.47 $457 - $728	-295 Reduced 9.89%	2,687 $4,000
Q3 2022 Nov 10, 2022	SELL	$1.96 - $3.13 $4,506 - $7,195	-2,299 Reduced 43.53%	2,982 $6,000
Q2 2022 Aug 10, 2022	SELL	$2.64 - $4.84 $13,479 - $24,713	-5,106 Reduced 49.16%	5,281 $14,000
Q1 2022 May 12, 2022	BUY	$3.5 - $5.3 $20,569 - $31,148	5,877 Added 130.31%	10,387 $45,000
Q4 2021 Feb 10, 2022	BUY	$4.45 - $6.21 $14,796 - $20,648	3,325 Added 280.59%	4,510 $23,000
Q3 2021 Nov 10, 2021	BUY	$6.14 - $10.1 $7,275 - $11,968	1,185 New	1,185 $7,000

Others Institutions Holding NAUT

# of Institutions

Shares Held

64.3M

Call Options Held

1.9K

Put Options Held

100

View Full List

About Nautilus Biotechnology, Inc.

Ticker NAUT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,663,000
Market Cap $222M
Description
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was found...

More about NAUT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account